RxDoctor Payments DataLook up a doctor →

Vamsee Yaganti, MD

Interventional Cardiology · Salt Lake City, UTNPI 1255591194

Payments from drug & device makers

$725,278in general payments, 2019–2025

Across 1,008 payments — averaging $719.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$498K
  • W. L. Gore & Associates, Inc.$162K
  • Edwards Lifesciences$50K
  • Abbott$7K
  • Recor Medical Inc$4K
  • Abiomed$2K
  • plus $3K from 19 others

What the payments were for

  • Consulting fees$171,66544%
  • Speaking & faculty fees$133,80034%
  • Grants$13,5253%
  • Travel & lodging$42,41011%
  • Food & beverage$28,7547%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$725,278 in reported general payments places this provider in the 95th percentile of 45 interventional cardiology providers in Utah.

See all interventional cardiology providers in Utah

Medicare billing

Part B allowed, 2024
$322,803
Medicare patients
1,015
Services billed
2,579

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban232$257,303
XareltoRivaroxaban68$88,657
Repatha SureclickEvolocumab50$50,130
EntrestoSacubitril/Valsartan20$36,777
BrilintaTicagrelor44$28,070
Repatha SyringeEvolocumab19$13,890
FarxigaDapagliflozin Propanediol13$8,689
Metoprolol Succinate391$5,633
Atorvastatin Calcium612$5,160
Potassium Chloride228$3,393
Losartan Potassium375$3,325
ClopidogrelClopidogrel Bisulfate361$3,179
Carvedilol427$3,061
Torsemide111$2,516
Diltiazem 24hr Er (Cd)Diltiazem Hcl92$2,165

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$83$257,303232 claims
NovartisEntresto$54$36,77720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 45 interventional cardiology providers in Utah.

Other interventional cardiology in Salt Lake City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →